deltatrials
Completed OBSERVATIONAL NCT00799877

Chronic Plaque Psoriasis (Ps) Registry

A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)

Sponsor: AbbVie

Conditions Chronic Plaque Psoriasis
Updated 23 times since 2017 Last updated: Mar 12, 2024 Started: Sep 26, 2008 Primary completion: Feb 13, 2023 Completion: Feb 13, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00799877, this observational or N/A phase trial focuses on Chronic Plaque Psoriasis and remains completed. Sponsored by AbbVie, it has been updated 23 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Jul 2020 · 15 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jan 2022 · 9 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Apr 2024 · 7 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Apr 2024 — Jul 2024 [monthly]

    Completed

  5. Sep 2023 — Apr 2024 [monthly]

    Completed

▶ Show 18 earlier versions

  1. Jun 2023 — Sep 2023 [monthly]

    Completed

  2. May 2023 — Jun 2023 [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  3. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting

  4. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting

  5. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting

  6. Apr 2021 — Jan 2022 [monthly]

    Active Not Recruiting

  7. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting

  8. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting

  9. Apr 2019 — Jul 2020 [monthly]

    Active Not Recruiting

  10. Nov 2018 — Apr 2019 [monthly]

    Active Not Recruiting

  11. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting

  12. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting

  13. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting

    Phase: NA → None

  14. Feb 2018 — Apr 2018 [monthly]

    Active Not Recruiting NA

  15. Aug 2017 — Feb 2018 [monthly]

    Active Not Recruiting NA

  16. May 2017 — Aug 2017 [monthly]

    Active Not Recruiting NA

  17. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting NA

  18. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting NA

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus N, Denmark , Aberdeen, United Kingdom , Akron, United States , Alcorcón, Spain , Alicante, Spain , Alkmaar, Netherlands , Almelo, Netherlands , Alpharetta, United States , Amsterdam, Netherlands , Ann Arbor, United States and 262 more locations